BioSpace News Archive

Arizona company claims their products can treat Lyme disease, diabetes, Parkinson’s disease and more, but have not been approved for any use

The maximum tolerated dose (MTD) of TP-0903 was established during the Phase 1a portion of the study, allowing the study to advance to the Phase 1b stage.

Lantheus expands into immuno-oncology and pharmaceutical services business through the license of NanoMab’s NM-01, an anti-PD-L1 imaging biomarker, designed to evaluate tumor immune activity and potentially guide future patient selection for immuno-oncology treatment

Schrödinger today announced that Ramy Farid, Ph.D., chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. ET in New York, NY.

Rouven Bergmann, chief financial officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019, at 9 a.m. ET in New York.

Trovagene, Inc., a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division for the treatment of leukemias, lymphomas and solid tumor cancers, announces that the Company will host a business update conference call on Friday, June 7, 2019.

Sunniva Inc., a North American provider of cannabis products and services, released its financial results and management’s discussion and analysis for the three months ended March 31, 2019.

MedX Health Corp. announced its results for the three-months ended March 31, 2019, which are also available on SEDAR.

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate Communications.

As an advocate for the needs of researchers working at the forefronts of genomic research, Integrated DNA Technologies (IDT) releases its latest CRISPR enzyme Alt-R® Cas12a (Cpf1) Ultra. Cas12a Ultra is a powerful addition to IDT’s Alt-R CRISPR enzyme arsenal – its vastly improved performance makes it easier to achieve precision genome editing at new sites across genomes.